[Experimental and clinical data on the antitumor action of hydrazine sulfate].
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D012511:Sarcoma 37 / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013431:Sulfates / Q000627:therapeutic use; D013997:Time Factors
D000970:Antineoplastic Agents; D006834:Hydrazines; D013431:Sulfates
Eksperimental'nye i klinicheskie dannye o protivoopukholevom deĭstvii gidrazinsul'fata